𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass

✍ Scribed by B. S. DONAHUE; D. GAILANI; A. E. MAST

Book ID
109151492
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
238 KB
Volume
4
Category
Article
ISSN
1538-7933

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Matrix metalloproteinase-9, tissue inhib
Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and tumour necrosis factor Ξ± release during cardiopulmonary bypass
✍ H. F. Galley; G. D. Macaulay; N. R. Webster πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 116 KB

**Summary** An inflammatory response occurs during cardiac surgery involving cardiopulmonary bypass. Matrix metalloproteinase‐9 is an enzyme involved in cytokine processing and leucocyte extravasation. It is secreted as a pro‐enzyme in response to several inflammatory mediators and is inhibited by e

Co-localization of tissue factor and tis
Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis
✍ Kaikita, Koichi; Takeya, Motohiro; Ogawa, Hisao; Suefuji, Hisakazu; Yasue, Hirof πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 495 KB πŸ‘ 2 views

Tissue factor (TF) initiates the extrinsic pathway of blood coagulation by acting as a cofactor for Factor VII. Inhibition of the Factor VIIa-TF complex is mediated by the tissue factor pathway inhibitor (TFPI), which is a serine protease inhibitor with three Kunitz-type domains. The localization of